《大行報告》高盛下調港交所(00388.HK)目標價至400元 續列確信買入名單
高盛發表研究報告指,港交所(00388.HK)股價自年初至今下跌8%,跑輸恆生指數6個百分點。隨著今年第三季公布的數據,現貨市場交易量出現觸底反彈,該行將其2023及24財年的每股盈測由2022財年第四季的低位分別上調16%及9%。
該行將集團2023財年的每股盈測下調3%,而2024及25財年則分別為增加1%和下調4%,預計現金股本日均成交金額(ADT)今年將下降8%,並在2024及25財年分別增長14%和12%。該行維持對港交所的「買入」評級,續列入確信買入名單,目標價由410元小幅下調至400元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.